Provided by Tiger Trade Technology Pte. Ltd.

Cassava Sciences Inc

2.09
+0.04001.95%
Post-market: 2.160.0700+3.35%19:59 EST
Volume:469.68K
Turnover:994.79K
Market Cap:100.96M
PE:-0.95
High:2.16
Open:2.06
Low:2.06
Close:2.05
52wk High:4.98
52wk Low:1.15
Shares:48.31M
Float Shares:43.48M
Volume Ratio:0.78
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1976
EPS(LYR):-1.4620
ROE:-85.44%
ROA:-24.80%
PB:1.24
PE(LYR):-1.43

Loading ...

Cassava Sciences And 2 Other Promising Penny Stocks

Simply Wall St.
·
Feb 12

Cassava Sciences announces publication of Phase 3 results for simufilam

TIPRANKS
·
Jan 13

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

GlobeNewswire
·
Jan 13

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

GlobeNewswire
·
Dec 30, 2025

Cassava Sciences Inc: Will Pay $31.25 Mln for Complete Settlement and Release of All Claims

THOMSON REUTERS
·
Dec 23, 2025

Cassava Sciences: to Resolve Litigation Filed in US District Court in Texas

THOMSON REUTERS
·
Dec 23, 2025

Cassava Sciences Settles Securities Class Action for $31.25 Million

Reuters
·
Dec 23, 2025

Cassava Announces Agreement to Settle Securities Class Action Litigation

GlobeNewswire
·
Dec 23, 2025

Cassava Sciences Names Dawn C. Bir to Compensation Committee

Reuters
·
Dec 23, 2025

Correction: Investors Hope for Rate Cut Following Subdued Inflation as US Futures Mixed in Friday's Premarket Session

MT Newswires Live
·
Dec 19, 2025

Stocks to Watch: Nike, Cassava Sciences, KB Home

Dow Jones
·
Dec 19, 2025

Cassava Sciences Inc - on Dec 15, FDA Places Full Clinical Hold on Cassava's Trial - SEC Filing

THOMSON REUTERS
·
Dec 19, 2025

Cassava Sciences: Not Expected to Initiate Proof-of-Concept Clinical Trial for Simufilam in Tsc-Related Epilepsy in H1 2026 as Previously Disclosed

THOMSON REUTERS
·
Dec 19, 2025

FDA Puts Cassava Sciences Simufilam Trial on Full Clinical Hold

Reuters
·
Dec 19, 2025

Cassava Sciences Awards 2025 Cash Bonuses to Top Executives

Reuters
·
Dec 18, 2025

BRIEF-Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing

Reuters
·
Dec 03, 2025

Cassava Sciences Faces FDA Request for More Data on Simufilam Epilepsy Trial

Reuters
·
Dec 03, 2025

Director Robert Eugene Anderson Jr. acquires common shares of Cassava Sciences Inc

Reuters
·
Nov 26, 2025

Cassava Sciences Gains on Insider Buying

MT Newswires Live
·
Nov 26, 2025

Cassava Sciences CEO Richard Barry Acquires Common Shares

Reuters
·
Nov 25, 2025